METHODS AND COMPOSITIONS FOR TREATING CANCER WITH SIGLEC-9 ACTIVITY MODULATORS

The invention provides methods and compositions for treating Siglec-9 mediated cancer in a subject, where the cells of the cancer express sialylated Core-1-MUC1 glycoproteins that engage with Siglec-9 expressed on certain immune cells, for example, monocytes and macrophages of the subject. Prior to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BURCHELL, Joy Marilyn, BEATSON, Richard Esmond
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention provides methods and compositions for treating Siglec-9 mediated cancer in a subject, where the cells of the cancer express sialylated Core-1-MUC1 glycoproteins that engage with Siglec-9 expressed on certain immune cells, for example, monocytes and macrophages of the subject. Prior to treatment, the cancerous cells may evade the immune system of the host by binding Siglec-9 expressed by the immune cells, whereupon binding activates a number of pro-tumorigenic, Siglec-9 mediated activities in or via the immune cells. However, when treated with an inhibitor of Siglec-9 activity, the Siglec-mediated activities can be mitigated and the host immune system can recognize and elicit an immune response against the cancer cells expressing the sialylated Core-1 MUC1 glycoproteins.